<DOC>
	<DOCNO>NCT02504424</DOCNO>
	<brief_summary>This study design allow exist investigator continue access AeroForm Tissue Expander treat patient AirXpanders complete market application review process FDA .</brief_summary>
	<brief_title>AirXpanders AeroForm Tissue Expander System Breast Reconstruction</brief_title>
	<detailed_description>This prospective , multi-center , single arm , open-label , continue access clinical study . Subjects meet inclusion criterion agree participate study enrol implanted investigational AeroForm Tissue Expander . If subject bilateral procedure , AeroForm expander implant side . Subjects follow first post-operative visit explant tissue expander ( ) exchange permanent implant ( ) .</detailed_description>
	<criteria>Subject female age 1870 Subject require tissue expansion part breast reconstruction Subject able provide write informed consent Subject able willing comply study requirement Subject physical , perceptual cognitive capacity understand manage home dose regimen Subject 's tissue integrity unsuitable tissue expansion Subject residual gross malignancy intend expansion site Subject current prior infection intend expansion site Subject history fail tissue expansion breast reconstruction Subject comorbid condition determine Investigator place subject increase risk complication ( e.g. , severe collagen vascular disease , poorly manage diabetes ) Subject take concomitant medication determine Investigator place subject increase risk complication ( e.g. , Prednisone , Coumadin ) .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Tissue Expansion</keyword>
	<keyword>Tissue Expander</keyword>
	<keyword>Breast Tissue Expansion</keyword>
	<keyword>Breast Tissue Expander</keyword>
	<keyword>Breast Reconstruction</keyword>
	<keyword>2 Stage Breast Reconstruction</keyword>
</DOC>